Literature DB >> 16936778

Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.

S-Q Kuang1, X Ling, B Sanchez-Gonzalez, H Yang, M Andreeff, G Garcia-Manero.   

Abstract

To investigate if the tumor suppressor properties of p57KIP2 are dependent on its DNA methylation status, we studied the impact of several stress stimuli in leukemic cell lines with different p57KIP2 promoter DNA methylation levels. p57KIP2 reactivation was observed after stimulation with transforming growth factor-beta, other cytokines, high-density culture or serum withdrawal in p57KIP2 promoter unmethylated cells but not in methylated cells. In these cells, p57KIP2 reactivation required the use of a hypomethylating agent or a histone deacetylase inhibitor. Overexpression of p57KIP2 in p57KIP2 promoter methylated leukemic cell lines resulted in cell growth arrest and the induction of apoptosis. In contrast, overexpression of p57KIP2 in partially methylated cells only resulted in a moderate inhibition of cell growth and had no impact on apoptosis. Transduction of unmethylated cells expressing high levels of p57KIP2 with p57KIP2 short hairpin RNA resulted in increased cell proliferation. These results suggest that the tumor suppressive properties of p57KIP2 in leukemia may depend on the intrinsic promoter DNA methylation status of the gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936778     DOI: 10.1038/sj.onc.1209907

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.

Authors:  Wei-Gang Tong; William G Wierda; E Lin; Shao-Qing Kuang; B Nebiyou Bekele; Zeev Estrov; Yue Wei; Hui Yang; Michael J Keating; Guillermo Garcia-Manero
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

2.  Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.

Authors:  Shao-Qing Kuang; Hao Bai; Zhi-Hong Fang; Gonzalo Lopez; Hui Yang; Weigang Tong; Zack Z Wang; Guillermo Garcia-Manero
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

3.  Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Authors:  Christopher B Benton; Deborah A Thomas; Hui Yang; Farhad Ravandi; Michael Rytting; Susan O'Brien; Anna R Franklin; Gautam Borthakur; Samuel Dara; Monica Kwari; Sherry R Pierce; Elias Jabbour; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

4.  A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells.

Authors:  Oriella Andresini; Agnese Ciotti; Marianna N Rossi; Cecilia Battistelli; Mariarosaria Carbone; Rossella Maione
Journal:  Epigenetics       Date:  2016-09-09       Impact factor: 4.528

Review 5.  Epigenetics of acute lymphocytic leukemia.

Authors:  Guillermo Garcia-Manero; Hui Yang; Shao-Qing Kuang; Susan O'Brien; Deborah Thomas; Hagop Kantarjian
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

6.  Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice.

Authors:  Sabine Müller-Brüsselbach; Martin Kömhoff; Markus Rieck; Wolfgang Meissner; Kerstin Kaddatz; Jürgen Adamkiewicz; Boris Keil; Klaus J Klose; Roland Moll; Andrew D Burdick; Jeffrey M Peters; Rolf Müller
Journal:  EMBO J       Date:  2007-07-19       Impact factor: 11.598

7.  Aberrant EPHB4 gene methylation and childhood acute lymphoblastic leukemia.

Authors:  Yuhua Li; Huihui Wang; Xiaowen Chen; Huirong Mai; Changgang Li; Feiqiu Wen
Journal:  Oncol Lett       Date:  2017-08-16       Impact factor: 2.967

8.  Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Authors:  Elizabeth M Algar; Andrea Muscat; Vinod Dagar; Christian Rickert; C W Chow; Jaclyn A Biegel; Paul G Ekert; Richard Saffery; Jeff Craig; Ricky W Johnstone; David M Ashley
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

9.  Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.

Authors:  Shao-Qing Kuang; Zhihong Fang; Patrick A Zweidler-McKay; Hui Yang; Yue Wei; Emilio A Gonzalez-Cervantes; Yanis Boumber; Guillermo Garcia-Manero
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

Review 10.  Cellular Response upon Stress: p57 Contribution to the Final Outcome.

Authors:  Marianna Nicoletta Rossi; Fabrizio Antonangeli
Journal:  Mediators Inflamm       Date:  2015-09-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.